Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3743
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAnderson, G. J.en
dc.contributor.authorKlein, K.en
dc.contributor.authorHartel, G.en
dc.contributor.authorWainwright, Claireen
dc.contributor.authorBell, S. C.en
dc.contributor.authorReid, D. W.en
dc.contributor.authorSmith, D. J.en
dc.date.accessioned2022-11-07T23:45:39Z-
dc.date.available2022-11-07T23:45:39Z-
dc.date.issued2019en
dc.identifier.citation683 , 2019, p. 12-17en
dc.identifier.otherRISen
dc.identifier.urihttp://dora.health.qld.gov.au/qldresearchjspui/handle/1/3743-
dc.description.abstractBackground and Objective: Genetic modifiers contribute to variable disease phenotype in cystic fibrosis (CF). We explored the association between mutations in the hemochromatosis (HFE) gene and disease severity in adults with CF. Methods: HFE genotyping was performed in 163 adults with CF attending a single centre. Results were correlated with lung disease severity, prevalence of CF-related diabetes (CFRD) and history of meconium ileus (MI) or distal intestinal obstruction syndrome (DIOS). Results: Subjects with the C282Y substitution in the HFE protein (C282Y mutation) had a lower FEV1 percentage predicted (54% versus 66%, p = 0.029) and accelerated rate of FEV1 decline (−110 mL versus −80 mL per year respectively, p < 0.001) compared to subjects with a normal HFE genotype. C282Y substitutions were associated with increased rates of CFRD (58% versus 33%, p = 0.026) and a trend towards increased MI or DIOS (38% versus 19%, p = 0.05). H63D HFE substitutions were associated with a more rapid rate of decline in forced vital capacity (p = 0.01) and increased risk of MI or DIOS (p = 0.02). Conclusions: In subjects with CF, the C282Y HFE substitution was associated with worse lung function, and increased rates of CFRD and gastrointestinal complications. The H63D HFE substitution also impacted on disease phenotype, but to a lesser extent. The results support a role for HFE gene mutations as modifiers of CF phenotype.L20011760042018-10-16 <br />2018-10-22 <br />en
dc.language.isoenen
dc.relation.ispartofGeneen
dc.titleMutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosisen
dc.typeArticleen
dc.identifier.doi10.1016/j.gene.2018.10.002en
dc.subject.keywordsintestine obstructionen
dc.subject.keywordslung diseaseen
dc.subject.keywordsmajor clinical studyen
dc.subject.keywordsmaleen
dc.subject.keywordsmedical historyen
dc.subject.keywordsmutational analysisen
dc.subject.keywordspriority journalen
dc.subject.keywordsrisk assessmenten
dc.subject.keywordsmeconium ileusen
dc.subject.keywordshemochromatosis proteinhepcidinen
dc.subject.keywordsadulten
dc.subject.keywordsarticleen
dc.subject.keywordscontrolled studyen
dc.subject.keywordscystic fibrosisen
dc.subject.keywordsdisease associationen
dc.subject.keywordsdisease severityen
dc.subject.keywordsfemaleen
dc.subject.keywordsforced expiratory volumeen
dc.subject.keywordsforced vital capacityen
dc.subject.keywordsgene functionen
dc.subject.keywordsgene identificationen
dc.subject.keywordsgene mutationen
dc.subject.keywordsgenetic associationen
dc.subject.keywordsgenetic risken
dc.subject.keywordsgenotypeen
dc.subject.keywordsHFE geneen
dc.subject.keywordshigh risk populationen
dc.subject.keywordshumanen
dc.relation.urlhttps://www.embase.com/search/results?subaction=viewrecord&id=L2001176004&from=exporthttp://dx.doi.org/10.1016/j.gene.2018.10.002 |en
dc.identifier.risid1638en
dc.description.pages12-17en
item.grantfulltextnone-
item.openairetypeArticle-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
Appears in Sites:Children's Health Queensland Publications
Show simple item record

Page view(s)

70
checked on Apr 22, 2025

Google ScholarTM

Check

Altmetric


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.